Cardiff Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cardiff Oncology, Inc. (CRDF) on September 30, 2020, regarding events occurring on September 29, 2020. The filing discloses the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten public offering of common stock.
- Shares Offered: 6,500,000 shares.
- Offering Price: $13.50 per share.
- Gross Proceeds: Approximately $88 million (before underwriting discounts, commissions, and offering expenses).
- Underwriters: Cowen and Company, LLC and Piper Sandler & Co. (as representatives).
- Expected Closing Date: On or about October 2, 2020.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations. It focuses solely on the capital raise transaction.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the issuance of 6.5 million new shares. To support the offering, the Company, its directors, executive officers, and their affiliated entities have agreed to a 90-day lock-up period. During this time, they cannot sell or transfer any shares of Common Stock without the written consent of the underwriters' representatives.
Outlook, Risks, and Management Commentary
The Company issued press releases on September 29, 2020, announcing both the proposed offering and the final pricing. The offering is subject to customary closing conditions. The filing incorporates the Underwriting Agreement by reference, which contains customary representations, warranties, covenants, and indemnification obligations. No specific operational guidance or risk factors beyond standard underwriting terms are detailed in the text of this specific 8-K.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the actual closing date of the offering (expected October 2, 2020).
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check subsequent filings for the use of proceeds and updated cash position.